OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On January 8, 2018, Oxford Immunotec Global PLC (the “Company”) issued a press release announcing its preliminary revenue for the fourth quarter and full year ended December 31, 2017.A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
Item 2.02 Regulation FD Disclosure
During the week of January 8, 2018, the Company is holding meetings with investors discussing, among other topics, an overview of the Company’s business and growth strategy. A copy of the investor presentation, which is available at www.oxfordimmunotec.com, is furnished as Exhibit 99.2 to this Form 8-K and incorporated herein by reference.
Information in the presentation contains forward-looking statements regarding future events and performance of the Company. All such forward-looking statements are based largely on the Company’s experience and perception of current conditions, trends, expected future developments and other factors, and on management’s expectations, and are subject to risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those factors described in the presentation and in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.
In accordance with General Instruction B.2 of Form 8-K, the information in each of Item 2.02 and Item 2.02 of this Form 8-K and in the press release attached as Exhibit 99.1 and the presentation attached as Exhibit 99.2 is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings whether made before or after the date hereof or any other document under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Exhibit Description |
|
99.1 |
Press Release dated January 8, 2018 |
|
99.2 |
Investor Presentation |
Oxford Immunotec Global PLC ExhibitEX-99.1 2 ex_102768.htm EXHIBIT 99.1 ex_102768.htm Exhibit 99.1 Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Year 2017 OXFORD,…To view the full exhibit click here
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.
